![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » TOPOTARGET'S SAVENE APPROVED IN EUROPE; FDA ISSUES APPROVABLE LETTER
TOPOTARGET'S SAVENE APPROVED IN EUROPE; FDA ISSUES APPROVABLE LETTER
August 4, 2006
The European Commission has granted TopoTarget marketing approval for the company's first product, Savene, a drug that protects a patient´s tissue from accidental exposure to anthracyclines, the anti-cancer agents administered during chemotherapy. Furthermore, the FDA has issued an approvable letter for the drug (named Totect in the U.S.) requesting additional data.
Chemotherapy with anthracyclines is a cornerstone in the treatment of breast cancer and leukemia. Until now there has been no authorized treatment or prevention of the serious tissue damage that may result from accidents in chemotherapy.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct